Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RNA splicing as a therapeutic target in myelodysplastic syndromes.

Seminars in hematology - 1 Dec 2024

Tseng Chun-Chih, Obeng Esther A

Abstract excerpt

Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological disorders and are more commonly found in people over the age of 60. MDS patients exhibit peripheral blood cytopenias and carry an increased risk of disease progression to acute myeloid leukemia (AML). Splicing factor mutations (including genes SF3B1, SRSF2, U2AF1, and ZRSR2) are early events identified in more than 50% of MDS cases....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SF3B1 gene
Share to SRSF2 gene
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myelodysplastic Syndromes

Share to RNA Splicing

Share to RNA Splicing Factors

Share to Spliceosomes

Source

Identifiers

PMID: 39542752
DOI: 10.1053/j.seminhematol.2024.10.005

Genes

SF3B1
SRSF2
U2AF1
ZRSR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RNA splicing as a therapeutic target in myelodysplastic syndromes.PMID 39542752Read ↗

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.Semantic proximity Read ↗

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.Semantic proximity Read ↗

Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity.Semantic proximity Read ↗

Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.Semantic proximity Read ↗

Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.Semantic proximity Read ↗

Mechanistic Insights of Aberrant Splicing with Splicing Factor Mutations Found in Myelodysplastic Syndromes.Semantic proximity Read ↗

[Role of Aberrant Splicing in Pathogenesis of Myelodysplastic Syndromes-Review].Semantic proximity Read ↗

Splicing factor mutations in myelodysplasia.Semantic proximity Read ↗

Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.Semantic proximity Read ↗

Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.Semantic proximity Read ↗

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.Semantic proximity Read ↗

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.